Compare BXSL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | DNTH |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | 2018 | 2018 |
| Metric | BXSL | DNTH |
|---|---|---|
| Price | $23.93 | $89.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $24.66 | ★ $140.80 |
| AVG Volume (30 Days) | ★ 1.2M | 660.0K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 12.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $159.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.47 | $32.28 |
| 52 Week High | $28.59 | $117.88 |
| Indicator | BXSL | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 35.61 |
| Support Level | $23.26 | $89.21 |
| Resistance Level | $25.00 | $91.04 |
| Average True Range (ATR) | 0.35 | 4.60 |
| MACD | -0.12 | -1.13 |
| Stochastic Oscillator | 8.85 | 23.83 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.